Orthocell

26/05/2026

From surgeon education and clinical engagement to investor discussions, our team is preparing for a strong lineup of upcoming industry events across Australia and New Zealand.

📍 Orthocell Nerve Symposium
12 June | Sydney
Now in its fourth year, the Orthocell Nerve Symposium is an advanced educational program designed to provide Orthopaedic and Plastic Surgeons with a broad understanding of peripheral nerve repair and regeneration, including nerve transfer techniques using our collagen-based nerve repair technology, Remplir™. Featuring an international faculty, cadaveric workshops and clinical discussions focused on improving surgical decision-making and patient outcomes.

📍 Plastic Surgery Congress (PSC)
24–25 July | Brisbane
One of Australia’s leading plastic and reconstructive surgery meetings, bringing together surgeons and industry from across the sector. Orthocell’s distribution partner, Device Technologies, will be showcasing Remplir™ throughout the event.

📍 20th Bioshares Biotech Summit
6–7 August | Queenstown, New Zealand
Our executive team will be heading across the Tasman for Bioshares, a key biotech and healthcare investment forum connecting emerging companies with investors and sector stakeholders.

We look forward to seeing you there.

21/05/2026

Orthocell CEO Paul Anderson recently joined the ASX Briefs podcast to discuss the Company’s strong commercial momentum and global expansion.

In the episode, Paul shares how Orthocell is entering a high-growth revenue phase, supported by record Q3 FY26 revenue, rapid US adoption of Remplir™ and growing hospital access across key markets.

Orthocell’s regenerative medicine platforms supports the repair of bones, nerves and tendons, and including Remplir™, its breakthrough collagen nerve repair product.

🎧 Listen to the full podcast here: https://open.spotify.com/episode/3sCKlChI4a1xZGzSrC3QUi?si=qj6O8A9ARMORti3gkqdzbg

ASX BRIEFS · Episode

20/05/2026

We are at AusMedTech26 in Perth today. If you are attending, join Orthocell CEO and Managing Director Paul Anderson in two key sessions:

👉11.25 AM – 12.20 PM
Paul will chair the panel discussion “Unlocking the next horizon in MedTech”, exploring the technologies, pathways and partnerships shaping the next wave of innovation across the sector.

👉4.30 PM
Paul will also join the panel discussion “How to balance the optimism for success with the reality of surviving setbacks when running a healthcare venture”, bringing his experience leading Orthocell through commercialisation, regulatory milestones and international expansion.

Across both sessions, Paul will share insights on building resilience, navigating challenges and driving long‑term growth in healthcare innovation.

$OCC

15/05/2026

Orthocell Ltd’s Chief Operations Officer, Alex McHenry, and Chief Financial Officer, Jim Piper, attended the Canaccord Genuity Australia Rapid Insights Conference in Sydney yesterday.

The conference brings institutional investors together with leading growth‑stage companies across key sectors, including Healthcare, where Orthocell continues to advance regenerative medicine innovation.

It was a valuable opportunity to share our growth strategy, connect with investors, and participate in roundtable discussions alongside 150 attendees exploring market trends and opportunities.

$OCC

14/05/2026

Orthocell is exhibiting at the International Congress of Orthoplastic Surgery (ICOS), sharing insights on Remplir™, our flagship nerve repair device.

🗓️ 14–16 May
📍 Grossman School of Medicine, New York University (NYU)

We look forward to connecting with colleagues in New York to discuss advances in peripheral nerve repair.

$OCC

07/05/2026

What’s On | Upcoming Events for OCC

Orthocell will be participating in several key surgical education events this month. Our team will be on site to discuss Remplir™, our flagship nerve repair device, and its role in peripheral nerve reconstruction.

International Congress of Orthoplastic Surgery
🗓️ May 14–16
📍 New York, NY
👤 Featuring Dr. Jacques Hacquebord

Global Nerve Foundation (GNF) Basic Nerve Course & Fellows Course
🗓️ May 16
📍 University of Utah

Washington University Nerve Course
🗓️ May 29–30
📍 Washington University Medical Center, St. Louis

We look forward to connecting with colleagues and advancing the conversation around nerve repair innovation.

$OCC

01/05/2026

What’s On | Upcoming Events for OCC in Australia

The Orthocell team is looking forward to attending these upcoming events across Australia.

Please drop by to learn more about our suite of Australian-made medical devices spanning nerve, tendon and bone repair.

AusBiotech | Medtech Unlocked�
🗓️ May 19–21, 2026�
📍 Perth

Orthocell Nerve Symposium�
🗓️ June 12�
📍 Sydney

2026 ASPS Plastic Surgery Congress
🗓️ July 24–25�
📍 Brisbane

We look forward to seeing you there.

$OCC

30/04/2026

Orthocell has shared that it has completed the first commercial sales of Remplir™ in the US75 million Canadian market, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device.

The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide majority national coverage across the Canadian market and position the Company to support surgeon and hospital adoption nationwide.

Orthocell has worked alongside its distributors on initial launch activities, including a KOL-led product roadshow across Canada (Vancouver to Toronto). The program featured Australian orthopaedic surgeon Dr Stuart Kirkham, who presented his clinical experience and use of Orthocell’s Remplir collagen nerve repair device to plastic and orthopaedic peripheral nerve surgeons. This activity supported product education and early engagement, contributing to the first commercial sales.

Following the Canadian launch, Orthocell will continue to work closely with its distributor network to onboard surgeons and establish active accounts, supported by the Company’s existing US-based marketing and medical education teams. This coordinated approach provides clinical engagement, training and operational efficiencies across the U.S. and Canada.

🔗 Read the ASX release: https://bit.ly/4tg90BW

$OCC

28/04/2026

Orthocell (ASX: OCC) is pleased to announce the latest results from the ongoing Remplir™ Real World Evidence study, reinforcing strong and consistent clinical outcomes across a broad range of nerve repair procedures.

Based on performance data from 66 participants, these results further strengthen the clinical evidence base for Remplir, demonstrating an overall treatment success rate of 89.7% across 78 procedures, with no post-treatment complications or adverse effects reported.

Key outcomes include:

🔹 90.3% of motor nerve repairs achieved functional muscle recovery
🔹 89.4% of nerve decompression procedures delivered significant improvement or complete symptom relief

These results are consistent with earlier findings and previously published clinical data, reinforcing Remplir’s predictable performance across a broad range of nerve repair applications.

Adoption of Remplir continues to expand, with more than 300 surgeons across 220+ hospitals in Australia now using the product. In the United States, more than 49 surgeons across 55+ hospitals have purchased Remplir, reflecting growing confidence supported by the expanding body of clinical evidence.

The data will play an important role in driving continued commercial growth in the U.S. and upcoming European markets, with regulatory approval expected in H2 CY26.

Read the ASX release: https://bit.ly/42zGOyI

$OCC

22/04/2026

Orthocell proudly congratulates Professor Fiona Wood AM on being awarded the Lifetime Achievement Award by the American Burn Association.

This prestigious honour recognises Professor Wood’s global leadership in burn care and her enduring contribution to advancing treatment, research and patient outcomes over more than three decades.

Professor Wood is internationally recognised for pioneering innovations that have transformed the treatment of burn injuries, including the development of technologies that enable more effective wound closure and improved recovery outcomes. Her work has helped shape modern burn care and continues to influence clinical practice worldwide.

Orthocell is proud to have Professor Wood on its Board, where her deep clinical expertise, experience in translating innovation into practice and commitment to improving patient outcomes continue to inform and strengthen the Company’s work.

This recognition reflects an extraordinary career and a legacy that continues to shape the future of burn care globally.

$OCC

21/04/2026

Tylah Tully sits down with Orthocell Managing Director and CEO Paul Anderson to discuss Orthocells growing traction in the US market, delivering strong revenue growth with expansion across key hospital networks.

Orthocell (ASX:OCC) gains traction in the US market, delivering strong revenue growth and expanding access across key hospital networks.